Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 2004

View Archived Issues

Gabapentin delays ejaculation in a case of PE / News in Context

New angiotensin II receptor agonists covered by Vicore patent

New GLP-2 derivatives and their use in gastrointestinal disorders

GSK researchers identify new ROCK inhibitors for use in cardiovascular and other disorders

Merck claims prostaglandin analogues as EP4 receptor agonists for ocular and bone conditions

Emory University patents CXCR4 antagonists and their use in cancer

Novel method for treatment for neutrophil-mediated conditions

Pharmacokinetic interactions with UK-427857 studied

Selective TRPV1 receptor antagonist shows analgesic effect in vivo

CAT and AstraZeneca form alliance in inflammatory disorders

Nonendocannabinoid inhibitor of anadamide inactivation shows analgesic effects in pain model

Alfacell and NCI pursue development of RN-321

Novel 1beta-methylcarbapanem shows promising antibacterial activity

Vesicare approved by FDA

Poor bioavailability results for R-803 in phase I/II HCV study

Multitarget antimalarial vaccine effective in non-human primates

BEYOND study of Betaferon recommended to continue

NDA submission for indiplon modified release

New Roche study investigates response rates to HCV therapy in Latinos

Synta closes financing round

Bayer signs development agreement for longer-acting Kogenate

EHT-0202 to enter phase IIa proof-of-concept study in Alzheimer's in 2005

European approval for Bayer's acquisition of Roche consumer health business

TMC-114 active against resistant HIV-1

Long-term antiviral activity of TMC-125 seen in HIV-infected patients

Liarozole reported safe and effective in the treatment of ichthyosis and psoriasis

Cilansetron improves quality of life of patients with diarrhea-predominant IBS

Study of interferon gamma-1b in idiopathic pulmonary fibrosis continues

Clinical data confirm the benefits of AGI-1067 in atherosclerosis

Phase II data on the therapeutic benefits of dexanabinol in CABG-associated cognitive impairment

Results of phase I study of FG-3019 in idiopathic pulmonary fibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...